Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Evorpacept improved tumor response in patients with HER2-positive gastric/GEJ cancer, becoming the first ... TRP to an assumed RP control ORR of 30% Secondary endpoints of PFS and OS were immature ...

We anticipate achieving several additional clinical milestones in the near-term that could advance evorpacept towards being a best-in-class, combinable therapeutic across a wide range of cancer types ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa continue to perform ... based on alpha-emitting isotopes for rare cancers. We will keep you updated as we continue to access ...

India observes National Cancer Awareness Day annually on November 7th, coinciding with Marie Curie's birthday, to combat the rising incidence of cancer. The day emphasizes the importance of early ...

Receiving radiation therapy for breast cancers harboring TP53 germline variants may cause secondary cancers, but risk estimates are unconfirmed. Patients with breast cancer who carry TP53 germline ...